Edition:
United Kingdom

Cosmo Pharmaceuticals NV (COPN.S)

COPN.S on Swiss Exchange

131.60CHF
4:31pm GMT
Change (% chg)

CHF0.50 (+0.38%)
Prev Close
CHF131.10
Open
CHF130.60
Day's High
CHF132.70
Day's Low
CHF129.00
Volume
11,212
Avg. Vol
19,122
52-wk High
CHF181.80
52-wk Low
CHF124.90

Select another date:

Thu, Feb 1 2018

BRIEF-Cosmo Pharmaceuticals And Pharmascience Establish License And Supply Agreement‍​

* COSMO PHARMACEUTICALS AND PHARMASCIENCE ESTABLISH LICENSE AND SUPPLY AGREEMENT FOR ELEVIEW, METHYLENE BLUE MMX, RIFAMYCIN MMX AND QOLOTAG FOR CANADA​

BRIEF-Cosmo Pharmaceuticals: update on commercialization of Rifamycin SV MMX

* ‍ITS PARTNER DR. FALK PHARMA HAS FILED FOR MARKETING AUTHORIZATION OF RIFAFALK 200MG IN GERMANY​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cosmo Pharmaceuticals: update on lawsuit against patent infringement on Uceris‍​

* DISTRICT OF DELAWARE HAS RULED NON-INFRINGEMENT OF ACTAVIS ANDA PRODUCT FOR GENERIC VERSION OF VALEANT’S UCERIS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cosmo Pharmaceuticals and Fujifilm establish distribution agreement for Eleview for Europe & South Africa

* WITH FUJIFILM ESTABLISH DISTRIBUTION AGREEMENT FOR ELEVIEW® FOR EUROPE & SOUTH AFRICA​

BRIEF-Cosmo Pharmaceuticals: FDA grants QIDP and fast track designations for Aemcolo​

* ‍FDA GRANTS COSMO PHARMACEUTICALS BOTH QIDP AND FAST TRACK DESIGNATIONS FOR AEMCOLO​ Source text - http://bit.ly/2zvcXIc Further company coverage: (Gdynia Newsroom)

BRIEF-Cosmo Pharmaceuticals says ‍FDA accepts new drug application submission for methylene blue mmx​

* ‍FDA ACCEPTS NEW DRUG APPLICATION SUBMISSION FOR COSMO PHARMACEUTICAL'S METHYLENE BLUE MMX(TM)​

BRIEF-Cosmo Pharmaceuticals and Olympus America establish co-promotion agreement for Eleview

* COSMO PHARMACEUTICALS AND OLYMPUS AMERICA INC. ESTABLISH CO-PROMOTION AGREEMENT FOR ELEVIEW(TM) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Select another date: